BVF INC/IL
SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$3.04B2026 Q3
Positions47
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.66.0%
What Changed This Quarter?
Top Holdings
RVMD
Revolution Medicines
16.6%
KYMR
Kymera Therapeutics
14.2%
GHRS
GH Research
6.7%
MLTX
MoonLake Immunotherapeutics
6.2%
XNCR
Xencor
5.1%
NKTR
Nektar Therapeutics
4.2%
ALKS
Alkermes
3.8%
STOK
Stoke Therapeutics
3.1%
New / Increased
4 new · 7 increased
PYXSNEW
Pyxis Oncology
0.9%
ALECNEW
Alector
0.6%
Tcgx Acquisit…NEW
TCGX Acquisition
0.2%
Research Alli…NEW
Research Alliance Corp
0.2%
TYRA
Tyra Biosciences
3.0%
+185.6%
Entera Bio
Entera Bio
1.6%
+603.2%
ALKS
Alkermes
3.8%
+32.1%
STOK
Stoke Therapeutics
3.1%
+41.7%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.